Page 2 - Opal Computational Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Novo Nordisk, Valo Health $2 7B Deal Taps AI to Develop New Treatments for Cardiometabolic Diseases
healthleadersmedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthleadersmedia.com Daily Mail and Mail on Sunday newspapers.
Novo Nordisk and Valo Health agree deal worth up to $3 3bn
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Novo Nordisk A/S and Valo Health, Inc. announced they have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases based on Valo’s large human dataset and computation powered by artificial intelligence (AI). The collaboration between the two organizations will leverage the capabilities of Valo’s Opal Computational Platform™ including access to real-world patient data, AI-enabled small molecule discovery and Biowire® human tissue modelling platform designed to speed up the discovery and development process.
Denmark’s Novo Nordisk struck a deal with U.S.-based health tech firm Valo Health to use AI to discover and develop treatments for cardiometabolic diseases such as heart attack, stroke, and diabetes.
vimarsana © 2020. All Rights Reserved.